NCT01286753View on ClinicalTrials.gov

A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

November 30, 2014

Study Completion Date

May 31, 2015

Conditions
Neoplasms
Interventions
DRUG

Vemurafenib

Vemurafenib 960 mg orally twice daily.

Trial Locations (16)

10017

New York

19104

Philadelphia

20133

Milan

21231

Baltimore

56124

Pisa

60637

Chicago

69008

Lyon

75651

Paris

77030

Houston

90502

Torrance

94805

Villejuif

06510

New Haven

02114

Boston

02215

Boston

9700 RB

Groningen

2300 RC

Leiden

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01286753 - A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation | Biotech Hunter | Biotech Hunter